London, United Kingdom

Robert J Young

This inventor holds 4 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent. Top assignees: Lonza Inc., Lonza Walkersville, Inc.. Active years: 2020-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Robert J Young. Retrieved from https://idiyas.com/inventor/robert-j-young-n0mwh9a9

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4 

% Patents Active = 100.0

 

Average Co-Inventor Count = 3.7

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • Berkshire, GB (2020 - 2022)
  • London, GB (2023)

Company Filing History:


Years Active: 2020-2023

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovations of Robert J Young

Introduction

Robert J Young is a prominent inventor based in London, GB. He has made significant contributions to the field of biotechnology, particularly in the development of methods for producing adeno-associated viruses and cellular reprogramming techniques. With a total of four patents to his name, Young's work has the potential to impact therapeutic applications in regenerative medicine.

Latest Patents

One of Young's latest patents focuses on mammalian cells for producing adeno-associated viruses. This patent describes a mammalian cell that includes at least four distinct recombination target sites, an adenovirus gene, and a promoter that is operatively linked to the adenovirus gene. The integration of these components allows for the generation of a recombinant adeno-associated virus producer host cell. Additionally, he has developed methods for using this AAV producer host cell to produce, package, and purify recombinant adeno-associated viruses.

Another significant patent by Young involves methods for nuclear reprogramming using synthetic transcription factors. This disclosure outlines techniques for reprogramming mammalian somatic cells by regulating the expression of endogenous cellular genes. By activating embryonic stem cell-associated genes and suppressing somatic cell-specific genes, the methods enable faster and more efficient nuclear reprogramming. The resulting cells can be utilized for therapeutic applications in diseases amenable to stem cell therapy.

Career Highlights

Throughout his career, Robert J Young has worked with notable companies such as Lonza Inc. and Lonza Walkersville, Inc. His expertise in biotechnology has allowed him to contribute to advancements in the field, particularly in the areas of gene therapy and cellular reprogramming.

Collaborations

Young has collaborated with esteemed colleagues, including James Budge and Christopher Mark Smales. These partnerships have further enhanced his research and development efforts in biotechnology.

Conclusion

Robert J Young's innovative work in biotechnology, particularly in the areas of adeno-associated virus production and cellular reprogramming, showcases his significant contributions to the field. His patents and collaborations reflect a commitment to advancing therapeutic methods that could benefit regenerative medicine.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…